rss

This article has a correction

Please see: J Med Genet 2007;44:160

J Med Genet 43:893-896 doi:10.1136/jmg.2006.044222
  • Letters to JMG

Polyalanine and polyserine frameshift products in Huntington’s disease

  1. J E Davies,
  2. D C Rubinsztein
  1. Department of Medical Genetics, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge, UK
  1. Correspondence to:
 D C Rubinsztein
 Department of Medical Genetics, Cambridge Institute for Medical Research, Wellcome/MRC Building, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2XY, UK; dcr1000{at}hermes.cam.ac.uk
  • Received 23 May 2006
  • Accepted 17 June 2006
  • Revised 12 June 2006
  • Published Online First 26 June 2006

Abstract

Codon reiteration disorders are caused by abnormal expansions of either polyglutamine or polyalanine tracts within the coding region of a protein. These mutations impair normal protein folding, resulting in aggregate formation in the affected tissues. Huntington’s disease is the most common of the nine disorders caused by polyglutamine expansion mutations. The most extensively studied polyalanine expansion disorder is oculopharyngeal muscular dystrophy. There may be a link between diseases caused by polyglutamine and polyalanine expansion mutations as it has been shown that the expanded CAG/polyglutamine tract within the SCA3 gene can shift to the CGA/polyalanine frame. Here, we show that this frameshifting phenomenon is more widespread and occurs in Huntington’s disease. We have shown both +1 frameshift and +2 frameshift products (which may contain polyalanine or polyserine tracts, respectively) in human postmortem Huntington’s disease brains and in a transgenic mouse model of Huntington’s disease. Our data suggest that +1 and +2 frameshift products are generated at low levels. This may be relevant to the pathogenesis of human Huntington’s disease, as we have previously shown that both polyserine and polyalanine-containing proteins are modifiers of mutant huntingtin toxicity, with low expression levels of polyalanine-containing proteins having a protective effect.

Footnotes

  • Published Online First 26 June 2006

  • Finding: This work was funded by the Wellcome Trust (Senior Clinical Fellowship to DCR) and an MRC programme grant to DCR (with S Brown).

  • Competing interests: None.